dofequidar has been researched along with paclitaxel in 2 studies
Studies (dofequidar) | Trials (dofequidar) | Recent Studies (post-2010) (dofequidar) | Studies (paclitaxel) | Trials (paclitaxel) | Recent Studies (post-2010) (paclitaxel) |
---|---|---|---|---|---|
40 | 2 | 5 | 31,874 | 5,729 | 15,395 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hirata, H; Matsuba, Y; Naito, M; Sato, S; Tsuruo, T | 1 |
Aoki, J; Kimura, Y; Kohno, M; Nakanishi, O; Ooka, H; Tsuruo, T | 1 |
2 other study(ies) available for dofequidar and paclitaxel
Article | Year |
---|---|
MS-209, a quinoline-type reversal agent, potentiates antitumor efficacy of docetaxel in multidrug-resistant solid tumor xenograft models.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Cycle; Cell Division; Cell Line; Docetaxel; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Inhibitory Concentration 50; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Mitosis; Models, Chemical; Neoplasm Transplantation; Paclitaxel; Quinolines; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Time Factors; Tumor Cells, Cultured | 2002 |
P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Caco-2 Cells; Cyclosporine; Cyclosporins; Humans; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Paclitaxel; Quinolines; Rats; Rats, Sprague-Dawley | 2002 |